PubRank

Brian D Lichty

Author PubWeight™ 43.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003 5.89
2 Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007 1.93
3 Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2009 1.68
4 A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther 2008 1.60
5 Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010 1.51
6 Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010 1.46
7 Cigarette smoke impacts immune inflammatory responses to influenza in mice. Am J Respir Crit Care Med 2006 1.38
8 A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 2010 1.38
9 Targeting tumor vasculature with an oncolytic virus. Mol Ther 2011 1.35
10 The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 2008 1.26
11 Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 2007 1.26
12 Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 2009 1.22
13 HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 2013 1.13
14 Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther 2010 1.12
15 Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res 2013 1.05
16 Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther 2012 1.03
17 Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther 2009 1.03
18 Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 2006 1.02
19 Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009 1.00
20 Cigarette smoke suppresses type I interferon-mediated antiviral immunity in lung fibroblast and epithelial cells. J Interferon Cytokine Res 2008 0.99
21 Strategies to enhance viral penetration of solid tumors. Hum Gene Ther 2011 0.97
22 IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res 2011 0.97
23 FimH can directly activate human and murine natural killer cells via TLR4. Mol Ther 2010 0.97
24 Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev 2010 0.93
25 IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells. J Immunol 2012 0.92
26 Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology 2013 0.88
27 Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. J Immunol 2010 0.88
28 Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy 2013 0.87
29 Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Mol Ther 2008 0.86
30 Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. Blood 2013 0.85
31 Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol 2011 0.84
32 ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol Ther 2012 0.82
33 Panorama from the oncolytic virotherapy summit. Mol Ther 2013 0.81
34 Using G-deleted vesicular stomatitis virus to probe the innate anti-viral response. J Virol Methods 2008 0.78
35 Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-κB activation. J Virol 2013 0.77
36 Correction: Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS One 2016 0.75